This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Michael A. Weber, MD

Arch Intern Med. 1979;139(1):93-95.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Saralasin (Sar 1, Ala 8, angiotensin II) is an intravenously administered, competitive antagonist of angiotensin II that is used to identify renin-dependent (angiotensinogenic) hypertension. It is soon to be made available for general use as a screening test in patients with suspected renovascular hypertension.

Although several analogues of angiotensin II have been synthesized, the widest clinical experience has been with saralasin. The octapeptide sequences of angiotensin II and saralasin are compared in the Table. The substitution of sarcosine for aspartic acid in position 1 allows saralasin to bind more firmly to angiotensin receptors and to have a longer duration of action,^1,2 whereas the substitution of alanine for phenylalanine in position 8 ensures that the interaction of saralasin with the receptors produces a substantially smaller stimulatory effect than that of angiotensin II.²

Since saralasin works through competitive inhibition of angiotensin II,³ its effects are best explained by an . . . [Full Text PDF of this Article]

Author Affiliations
From the Hypertension Section, Department of Medicine, Long Beach (Calif) Veterans Administration Hospital, and the University of California, Irvine.

Footnotes
Accepted for publication July 28, 1978.

Reprint requests to Hypertension Section, Veterans Administration Hospital, 5901 E Seventh St, Long Beach, CA 90822 (Dr Weber).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?